Hanmi Pharmaceutical has signed a licensing agreement for Kinex Pharmaceuticals to develop its Orascovery pump inhibitor for gastrointestinal treatments in India. The South Korea and U.S. companies have been partners in global development since 2011 except for in South Korea and Japan. Under the agreement, Kinex is to have full responsibility for developing Orascovery in India. Hanmi also has arrangements with other drugmakers in Australia and New Zealand and in Singapore. Release